Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

2.120 USD +0.140 (+7.07%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Abeona Therapeutics

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host... 
From GlobeNewswire News Releases
Leading Biotech Companies Receiving Orphan Drug Designation in 2017
Microcapspeculators.com News Commentary 
From PR Newswire
Stock Performance Review on Biotech Industry -- Radius Health, Abeona Therapeutics, Catalyst Biosciences, and Cerecor
From PR Newswire
Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights
Investor Conference Call to be held Tuesday, August 22nd at 10:00 am ET 
From GlobeNewswire News Releases
Top Companies Receiving Orphan Drug Designation in 2017
Microcapspeculators.com News Commentary 
From PR Newswire
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that Juan Ruiz,... 
From GlobeNewswire News Releases
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today guidance from a... 
From GlobeNewswire News Releases
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
Abeona’s Fourth Gene Therapy Program to Receive FDA Orphan Drug Designation 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
Company CEO to Present on Wednesday, June 7th at 3:30 PM ET 
From GlobeNewswire News Releases
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
Abeona’s Third Gene Therapy Program to Receive Rare Pediatric Disease Designation, expected to enable Priority Review Voucher 
From GlobeNewswire News Releases
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA... 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at Multiple Upcoming Conferences
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that members of the... 
From GlobeNewswire News Releases
Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced updated data from the... 
From GlobeNewswire News Releases
Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
Clinical Trial Notification (CTN) Enables Initiation at 3rd Global Site and Accelerates Enrollment in the ABO-102 MPS IIIA Gene Therapy Program 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
Company to Host Live Conference Call Briefing on Friday, May 12th at 10:00am EDT 
From GlobeNewswire News Releases
Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announces updated clinical data... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
Oral Presentation and Poster Sessions Highlighting EB-101 Gene Therapy Clinical Trial Updates and Natural History Study Data for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) 
From GlobeNewswire News Releases
Abeona to Present At Multiple Upcoming Conferences
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced... 
From GlobeNewswire News Releases
Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, is pleased to announce... 
From GlobeNewswire News Releases
Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
Management to Host Investor Conference Call on Monday, April 10th at 10:00 am ET to Provide Progress Report on Corporate Developments 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
Company COO to Present on Tuesday, March 14th & Tuesday, March 21st 
From GlobeNewswire News Releases
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European... 
From GlobeNewswire News Releases
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
Company COO to Present on Wednesday, March 8th at 9:20 AM EST 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
Company CEO to Present on Monday, March 6th at 11:45 am CST 
From GlobeNewswire News Releases
In Honor of International Rare Disease Day, Abeona Therapeutics (Nasdaq: ABEO) Set to Ring the Nasdaq Stock Market Closing Bell
From GlobeNewswire News Releases
Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that on February... 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that members of... 
From GlobeNewswire News Releases
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
Abeona Therapeutics Inc. (Nasdaq:ABEO): 
From GlobeNewswire News Releases
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
From ACCESSWIRE
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.